ଫୁଟିବାଟିନିବ

ଫୁଟିବାଟିନିବ
Clinical data
Trade names	Lytgobi
Synonyms	TAS-120
AHFS/Drugs.com	monograph
data	US DailyMed: Futibatinib;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one;
Chemical and physical data
Formula	C22H22N6O3
Molar mass	୪୧୮.୪୬ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2;
	InChI InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1; Key:KEIPNCCJPRMIAX-HNNXBMFYSA-N;

ଫୁଟିବାଟିନିବ (ଇଂରାଜୀ ଭାଷାରେ Futibatinib), ଲିଟଗୋବି ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ପିତ୍ତ ନଳୀ କର୍କଟ (କୋଲାଙ୍ଗିଓକାର୍ସିନୋମା) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୪] ଯେଉଁ କ୍ଷେତ୍ରରେ ଅସ୍ତ୍ରୋପଚାରଦ୍ୱାରା ଅପସାରଣ କରାଯାଇ ପାରିବ ନାହିଁ, ଫାଇବ୍ରୋବ୍ଲାଷ୍ଟ ଅଭିବୃଦ୍ଧି ଫ୍ୟାକ୍ଟର୍ ରିସେପ୍ଟର ୨ (FGFR୨) ଜିନ୍ ଫ୍ୟୁଜନ୍ ପଜିଟିଭ୍ ଏବଂ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସାରେ ବିଫଳ ହେଉଥିଲେ ଏହି ଔଷଧ ଦିଆଯାଏ ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନଖ ସମସ୍ୟା, ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, କୋଷ୍ଠକାଠିନ୍ୟ, ତରଳ ଝାଡ଼ା, ଥକ୍କା, ଶୁଖିଲା ପାଟି, କେଶହାନୀ, ବୃକ୍‌କ ସମସ୍ୟା, ଯକୃତ ସମସ୍ୟା, କମ୍ ରକ୍ତ ପ୍ଲାଟେଲେଟ୍, ସ୍ୱଳ୍ପ ଧଳା ରକ୍ତ କଣିକା, ଇଲେକ୍ଟ୍ରୋଲାଇଟ୍ ସମସ୍ୟା ଏବଂ ମୂତ୍ରନଳୀ ସଂକ୍ରମଣ ହୋଇପାରେ ।^[୧] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଖି ସମସ୍ୟା (ନେତ୍ରପଟଳ ସ୍ଖଳନ) ଏବଂ କୋମଳ ତନ୍ତୁ ମିନେରାଲାଇଜେସନ୍ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୧] ^[୫] ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର, ବିଶେଷକରି ଏକ ଏଫଜିଏଫଆର-୪ (FGFR1-4‌ ଇନହିବିଟର | ^[୧] ^[୫]

୨୦୨୨ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଫୁଟିବାଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୧] ୟୁରୋପରେ ଅନୁମୋଦନ ପାଇଁ ଏକ ଆବେଦନ ଦାଖଲ ହୋଇଥିବାବେଳେ ଏହା ୨୦୨୨ ସୁଦ୍ଧା ଅନୁମୋଦିତ ହୋଇ ନାହିଁ ।^[୪] ଅକ୍ଟୋବର ୨୦୨୨ ସୁଦ୍ଧା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ସମ୍ଭାବ୍ୟ ମୂଲ୍ୟ ଅସ୍ପଷ୍ଟ ଥିଲା ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Archive copy" (PDF). Archived (PDF) from the original on 2022-10-11. Retrieved 2022-12-04.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "FDA grants accelerated approval to futibatinib for cholangiocarcinoma". U.S. Food and Drug Administration. 30 September 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022. This article incorporates text from this source, which is in the public domain.
↑ "Drug Approval Package: Lytgobi". U.S. Food and Drug Administration (FDA). 8 November 2022. Archived from the original on 19 November 2022. Retrieved 18 November 2022.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Futibatinib". SPS - Specialist Pharmacy Service. 13 September 2021. Archived from the original on 20 August 2022. Retrieved 16 December 2022.
↑ ^୫.୦ ^୫.୧ "Orphan Drugs Take Specialty Rx Spotlight in 2022". www.specialtypharmacycontinuum.com. Archived from the original on 12 January 2023. Retrieved 12 January 2023.
↑ Kansteiner, Fraiser (3 October 2022). "Otsuka's Taiho Oncology bags approval for bile duct cancer med Lytgobi, teeing up showdown with BridgeBio and Incyte". Fierce Pharma (in ଇଂରାଜୀ). Archived from the original on 21 December 2022. Retrieved 21 December 2022.

[FDA2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Archive copy" (PDF). Archived (PDF) from the original on 2022-10-11. Retrieved 2022-12-04.{{cite web}}: CS1 maint: archived copy as title (link)

[FDA_futibatinib-2] "FDA grants accelerated approval to futibatinib for cholangiocarcinoma". U.S. Food and Drug Administration. 30 September 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022. This article incorporates text from this source, which is in the public domain.

[Lytgobi_Drug_Approval_Package-3] "Drug Approval Package: Lytgobi". U.S. Food and Drug Administration (FDA). 8 November 2022. Archived from the original on 19 November 2022. Retrieved 18 November 2022.

[SPS2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Futibatinib". SPS - Specialist Pharmacy Service. 13 September 2021. Archived from the original on 20 August 2022. Retrieved 16 December 2022.

[SPC2022-5] ୫.୦ ^୫.୧ "Orphan Drugs Take Specialty Rx Spotlight in 2022". www.specialtypharmacycontinuum.com. Archived from the original on 12 January 2023. Retrieved 12 January 2023.

[6] Kansteiner, Fraiser (3 October 2022). "Otsuka's Taiho Oncology bags approval for bile duct cancer med Lytgobi, teeing up showdown with BridgeBio and Incyte". Fierce Pharma (in ଇଂରାଜୀ). Archived from the original on 21 December 2022. Retrieved 21 December 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]